Current therapeutic strategies for invasive and metastatic bladder cancer

References

• Cancer Facts and FiguresAmerican Cancer Society2010 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdfAccessed March 31, 2011
   Google Scholar
• SEER Stat Fact Sheets: bladderNational Cancer Institute2010 http://seer.cancer.gov/statfacts/html/urinb.htmlAccessed March 31, 2011
   Google Scholar
• MostofiFKDavisCJSesterhennIAPathology of Tumors of the Urinary TractLyon, FranceSaunders1988
   Google Scholar
• ShelleyMDMasonMDKynastonHIntravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analysesCancer Treat Rev201036319520520079574
   PubMed Web of Science ®Google Scholar
• SolowayMSSoferMVaidyaAContemporary management of stage T1 transitional cell carcinoma of the bladderJ Urol200216741573158311912367
   PubMed Web of Science ®Google Scholar
• RaghavanDShipleyWUGarnickMBRussellPJRichieJPBiology and management of bladder cancerN Engl J Med199032216112911382181313
   PubMed Web of Science ®Google Scholar
• SteinJPLieskovskyGCoteRRadical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patientsJ Clin Oncol200119366667511157016
   PubMed Web of Science ®Google Scholar
• BabaianRJJohnsonDELlamasLAyalaAGMetastases from transitional cell carcinoma of urinary bladderUrology19801621421447404907
   PubMed Web of Science ®Google Scholar
• LeissnerJHohenfellnerRThuroffJWWolfHKLymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosisBJU Int200085781782310792159
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual7th edNew Yorkspringer2010
   Google Scholar
• KarlACarrollPRGschwendJEThe impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancerEur Urol200955482683519150582
   PubMed Web of Science ®Google Scholar
• KoppieTMVickersAJVoraKDalbagniGBochnerBHStandardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?Cancer2006107102368237417041887
   PubMed Web of Science ®Google Scholar
• SteinJPSkinnerDGThe role of lymphadenectomy in high-grade invasive bladder cancerUrol Clin North Am200532218719715862616
   PubMed Web of Science ®Google Scholar
• FleischmannAThalmannGNMarkwalderRStuderUEExtracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factorJ Clin Oncol200523102358236515800327
   PubMed Web of Science ®Google Scholar
• LoehrerPJSrEinhornLHElsonPJA randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyJ Clin Oncol1992107106610731607913
   PubMed Web of Science ®Google Scholar
• SaxmanSBPropertKJEinhornLHLong-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyJ Clin Oncol1997157256425699215826
   PubMed Web of Science ®Google Scholar
• von der MaaseHSengelovLRobertsJTLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerJ Clin Oncol200523214602460816034041
   PubMed Web of Science ®Google Scholar
• LinCCHsuCHHuangCYPrognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimensUrology200769347948417382149
   PubMed Web of Science ®Google Scholar
• KarakiewiczPIShariatSFPalapattuGSPrecystectomy nomogram for prediction of advanced bladder cancer stageEur Urol200650612541260 discussion 1261–125216831511
   PubMed Web of Science ®Google Scholar
• BochnerBHKattanMWVoraKCPostoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancerJ Clin Oncol200624243967397216864855
   PubMed Web of Science ®Google Scholar
• ShariatSFKarakiewiczPIPalapattuGSNomograms provide improved accuracy for predicting survival after radical cystectomyClin Cancer Res200612226663667617121885
   PubMed Web of Science ®Google Scholar
• KuczykMABokemeyerCSerthJp53 overexpression as a prognostic factor for advanced stage bladder cancerEur J Cancer199531 A13–14224322478652250
   PubMed Web of Science ®Google Scholar
• TsujiMKojimaKMurakamiYKanayamaHKagawaSPrognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimensBr J Urol19977933673729117215
   PubMedGoogle Scholar
• Lorenzo-RomeroJGSalinas-SanchezASGimenez-BachsJMPrognostic implications of p53 gene mutations in bladder tumorsJ Urol2003169249249912544295
   PubMed Web of Science ®Google Scholar
• SarkisASBajorinDFReuterVEPrognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVACJ Clin Oncol1995136138413907751883
   PubMed Web of Science ®Google Scholar
• HussainSAGanesanRHillerLProapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladderBr J Cancer200388458659212592374
   PubMed Web of Science ®Google Scholar
• CookePWJamesNDGanesanRBurtonAYoungLSWallaceDMBcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapyBJU Int200085782983510792161
   PubMed Web of Science ®Google Scholar
• DugganBWilliamsonKMolecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?)Curr Opin Urol200414527728615300148
   PubMed Web of Science ®Google Scholar
• TakataRKatagiriTKanehiraMPredicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profilingClin Cancer Res20051172625263615814643
   PubMed Web of Science ®Google Scholar
• HoffmannACWildPLeichtCMDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapyNeoplasia201012862863620689757
   PubMed Web of Science ®Google Scholar
• BellmuntJPaz-AresLCuelloMGene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyAnn Oncol200718352252817229776
   PubMed Web of Science ®Google Scholar
• TakaraKTsujimotoMKokufuMOhnishiNYokoyamaTUp-regulation of MDR1 function and expression by cisplatin in LLCPK1 cellsBiol Pharm Bull200326220520912576681
   PubMed Web of Science ®Google Scholar
• SmithSCBarasASDancikGA 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentLancet Oncol201112213714321256081
   PubMed Web of Science ®Google Scholar
• CooksonMSHerrHWZhangZFSolowaySSoganiPCFairWRThe treated natural history of high risk superficial bladder cancer: 15-year outcomeJ Urol1997158162679186324
   PubMed Web of Science ®Google Scholar
• TeramukaiSNishiyamaHMatsuiYOgawaOFukushimaMEvaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancerClin Cancer Res200612113914316397035
   PubMed Web of Science ®Google Scholar
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialInternational collaboration of trialistsLancet1999354917853354010470696
   PubMed Web of Science ®Google Scholar
• SherifARintalaEMestadONeoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2Scand J Urol Nephrol200236641942512623505
   PubMed Web of Science ®Google Scholar
• GrossmanHBNataleRBTangenCMNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerN Engl J Med2003349985986612944571
   PubMed Web of Science ®Google Scholar
• MalmstromPURintalaEWahlqvistRHellstromPHellstenSHannisdalEFive-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study GroupJ Urol19961556190319068618283
   PubMed Web of Science ®Google Scholar
• CortesiENeoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trialAmerican Society of Clinical Oncology Annual Meeting1995Philadelphia, PA
   Google Scholar
• ValeCLMeta-analysis Group, MCTU London UKNeoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaborationEur Urol2005482202205 discussion 205–20615939524
   PubMed Web of Science ®Google Scholar
• GriffithsG trialistsOboIco. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 TrialJ Clin Oncol201110.1200/JCO.2010.32.3139.
   Web of Science ®Google Scholar
• HerrHWFaulknerJRGrossmanHBSurgical factors influence bladder cancer outcomes: a cooperative group reportJ Clin Oncol200422142781278915199091
   PubMed Web of Science ®Google Scholar
• ScosyrevEElyBWMessingEMDo mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)BJU Int201010.1111/j.1464-410X.2010.09900.x.
   Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• DashAPettusJABochnerBHEfficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC)American Society of Clinical Oncology Annual Meeting 2007Chicago, IL
   Google Scholar
• SmithDCGrivasPDaignaultSA phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladderAmerican Society of Clinical Oncology Genitourinary cancer symposium2011Orlando, FL
   Google Scholar
• BlickCHallPPwintTAccelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladderAmerican Society of Clinical Oncology Genitourinary Cancer Symposium2011Orlando, FL, USA
   Google Scholar
• RodelCGrabenbauerGGKuhnRCombined-modality treatment and selective organ preservation in invasive bladder cancer: long-term resultsJ Clin Oncol200220143061307112118019
   PubMed Web of Science ®Google Scholar
• HoussetMDufourBDurduxCChretienYMejeanABailletFConcurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?Cancer Radiother19982Suppl 167s72s9749082
   PubMedGoogle Scholar
• ShipleyWUWinterKAKaufmanDSPhase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03J Clin Oncol19981611357635839817278
   PubMed Web of Science ®Google Scholar
• KachnicLAKaufmanDSHeneyNMBladder preservation by combined modality therapy for invasive bladder cancerJ Clin Oncol1997153102210299060542
   PubMed Web of Science ®Google Scholar
• HerrHWBajorinDFScherHINeoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcomeJ Clin Oncol1998164129813019552029
   PubMed Web of Science ®Google Scholar
• SternbergCNPansadoroVCalabroFCan patient selection for bladder preservation be based on response to chemotherapy?Cancer20039771644165212655521
   PubMed Web of Science ®Google Scholar
• DeVere WhiteRWLaraPNJrGoldmanBA sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)J Urol2009181624762480 discussion 2480–247119371909
   PubMed Web of Science ®Google Scholar
• CalabroFSternbergCNNeoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancerEur Urol200955234835818977070
   PubMed Web of Science ®Google Scholar
• ValeCLOn behalf of Meta-analysis Group MCTU, London, UKAdjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis CollaborationEur Urol2005482189199 discussion 199–20115939530
   PubMed Web of Science ®Google Scholar
• CognettiFRuggeriEMFeliciAAdjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trialAmerican Society of Clinical Oncology Annual Meeting2008Chicago, IL
   Google Scholar
• StadlerWMLernerSPGroshenSRandomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined nodenegative urothelial bladder cancer (UBC)American Society of Clinical Oncology Annual Meeting2009Chicago, IL
   Google Scholar
• Paz-AresGSolsonaEEstebanERandomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01studyAmerican Society of Clinical Oncology Annual Meeting2010Chicago, IL
   Google Scholar
• MeyersFJPalmerJMFreihaFSThe fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a northern california oncology group studyJ Urol19851346111811213903223
   PubMed Web of Science ®Google Scholar
• OliverRTEnglandHRRisdonRABlandyJPMethotrexate in the treatment of metastatic and recurrent primary transitional cell carcinomaJ Urol198413134834856230463
   PubMed Web of Science ®Google Scholar
• SolowayMSEinsteinACorderMPBonneyWProutGRJrCoombsJA comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A StudyCancer19835257677726347356
   PubMed Web of Science ®Google Scholar
• LorussoVPolleraCFAntimiMA phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder CancerEur J Cancer1998348120812129849481
   PubMed Web of Science ®Google Scholar
• McCaffreyJAHiltonSMazumdarMPhase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinomaJ Clin Oncol1997155185318579164195
   PubMed Web of Science ®Google Scholar
• PronzatoPViganiAPensaFVanoliMTaniFVairaFSecond line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancerAm J Clin Oncol19972055195219345341
   PubMed Web of Science ®Google Scholar
• HillcoatBLRaghavanDMatthewsJA randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tractJ Clin Oncol1989767067092654329
   PubMed Web of Science ®Google Scholar
• SternbergCNYagodaAScherHIMethotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer19896412244824582819654
   PubMed Web of Science ®Google Scholar
• LogothetisCJDexeusFHFinnLA prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumorsJ Clin Oncol199086105010552189954
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPHSchornagelJHRandomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924J Clin Oncol200119102638264611352955
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPSchornagelJHSeven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEur J Cancer2006421505416330205
   PubMed Web of Science ®Google Scholar
• von der MaaseHAndersenLCrinoLWeinknechtSDogliottiLWeekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trialAnn Oncol199910121461146510643537
   PubMed Web of Science ®Google Scholar
• AdamoVMagnoCSpitaleriGPhase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimenOncology200569539139816319510
   PubMed Web of Science ®Google Scholar
• BellmuntJvon der MaaseHMeadGMRandomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapyAmerican Society of Clinical Oncology Annual Meeting2007Chicago, IL
   Google Scholar
• BamiasAAravantinosGDeliveliotisCDocetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology GroupJ Clin Oncol200422222022814665607
   PubMed Web of Science ®Google Scholar
• DogliottiLCarteniGSienaSGemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trialEur Urol200752113414117207911
   PubMed Web of Science ®Google Scholar
• DreicerRManolaJRothBJPhase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumCancer200410081639164515073851
   PubMed Web of Science ®Google Scholar
• De SantisMBellmuntJMeadGRandomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatinbased chemotherapy: phase II – results of EORTC study 30986J Clin Oncol200927335634563919786668
   PubMed Web of Science ®Google Scholar
• DreicerRLiHCooneyMMWildingGRothBJPhase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology GroupCancer2008112122671267518459175
   PubMed Web of Science ®Google Scholar
• von der MaaseHLehmannJGravisGA phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urotheliumAnn Oncol200617101533153816873433
   PubMed Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet2011377976991492321376385
   PubMed Web of Science ®Google Scholar
• QuinnDIAparicioATsao-WeiDDPhase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) – Final report: a California Cancer Consortium-led NCI/CTEP-sponsored trialAmerican Society of Clinical Oncology Annual Meeting2010Chicago, IL
   Google Scholar
• MitraAPLinHDatarRHCoteRJMolecular biology of bladder cancer: prognostic and clinical implicationsClin Genitourin Cancer200651677716859582
   PubMed Web of Science ®Google Scholar
• HahnNMStadlerWMZonRMature results from Hoosier Oncology Group GU04–75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)American Society of Clinical Oncology Annual Meeting2010Chicago, IL
   Google Scholar
• HussainMVaishampayanUDuWRedmanBSmithDCCombination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancerJ Clin Oncol20011992527253311331332
   PubMed Web of Science ®Google Scholar
• WitteRSElsonPBonoBEastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinomaJ Clin Oncol19971525895939053481
   PubMed Web of Science ®Google Scholar
• MeluchAAGrecoFABurrisHA3rdPaclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research networkJ Clin Oncol200119123018302411408496
   PubMed Web of Science ®Google Scholar
• Di LorenzoGAutorinoRGiordanoAFOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladderJpn J Clin Oncol2004341274775015640506
   PubMed Web of Science ®Google Scholar
• CulineSRebillardXIborraFGemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot studyAnticancer Res2003232C1903190612820476
   PubMed Web of Science ®Google Scholar
• KruczynskiAHillBTVinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer propertiesCrit Rev Oncol Hematol200140215917311682323
   PubMed Web of Science ®Google Scholar
• BellmuntJTheodoreCDemkovTPhase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tractJ Clin Oncol200927274454446119687335
   PubMed Web of Science ®Google Scholar
• CulineSTheodoreCDe SantisMA phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenBr J Cancer200694101395140116622447
   PubMed Web of Science ®Google Scholar
• VaughnDJSrinivasSStadlerWMVinflunine in platinumpretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyCancer2009115184110411719536904
   PubMed Web of Science ®Google Scholar
• AlbersPParkSINiegischGRandomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment (German Association of Urological Oncology (AUO) trial AB 20/99)Ann Oncol201122228829420682548
   PubMed Web of Science ®Google Scholar
• SweeneyCJRothBJKabbinavarFFPhase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumJ Clin Oncol200624213451345716849761
   PubMed Web of Science ®Google Scholar
• ToppmeyerDLGoodinSIxabepilone, a new treatment option for metastatic breast cancerAm J Clin Oncol201033551652120023567
   PubMed Web of Science ®Google Scholar
• DreicerRLiSManolaJHaasNBRothBJWildingGPhase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology GroupCancer2007110475976317594721
   PubMed Web of Science ®Google Scholar
• WongYLitwinSPlimackEREffect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancerAmerican Society of Clinical Oncology Genitourinary Cancers Symposium2011Orlando, FL
   Google Scholar
• NecchiANicolaiNGuglielmiAPhase II study of pazopanib monotherapy for patients with relapsed/refractory urothelial cancer35th Europenan Society of Medical Oncology Congress2010Milan, Italy
   Google Scholar
• Availabe from: http://www.Clinicaltrials.gov2010Accessed March 31, 2011
   Google Scholar
• EbleJNSauterGEpsteinJISesterhennIAWorld Health OrganizationClassification of TumoursWorld Health Organization Classification of TumoursLyon, FranceIARC Press2004359
   Google Scholar
• DahmPGschwendJEMalignant non-urothelial neoplasms of the urinary bladder: a reviewEur Urol200344667268114644119
   PubMed Web of Science ®Google Scholar
• SwansonDALilesAZagarsGKPreoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladderJ Urol1990143137402294257
   PubMed Web of Science ®Google Scholar
• LughezzaniGSunMJeldresCAdenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortalityUrology201075237638120022091
   PubMed Web of Science ®Google Scholar
• ChoongNWQuevedoJFKaurJSSmall cell carcinoma of the urinary bladder. The Mayo Clinic experienceCancer200510361172117815700264
   PubMed Web of Science ®Google Scholar
• BexANieuwenhuijzenJAKerstMSmall cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancerUrology200565229529915708041
   PubMed Web of Science ®Google Scholar
• SpiessPEKassoufWSteinbergJRReview of the M.D. Anderson experience in the treatment of bladder sarcomaUrol Oncol2007251384517208137
   PubMed Web of Science ®Google Scholar
• RussoPBradyMSConlonKAdult urological sarcomaJ Urol1992147410321036 discussion 1036–10371552580
   PubMed Web of Science ®Google Scholar
• Lopez-BeltranAPacelliARothenbergHJCarcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 casesJ Urol19981595149715039554341
   PubMed Web of Science ®Google Scholar
• FroehnerMGaertnerHJManseckAWirthMPDurable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old manUrology200158579911711370
   PubMedGoogle Scholar